Drug Research
Engine Biosciences expands its digital drug discovery pipeline with $43M round
Drug discovery is a large and growing field, encompassing both ambitious startups and billion-dollar Big Pharma incumbents. Engine Biosciences is one of the former, a Singaporean outfit with an expert founding crew and a different approach to the business...
Drug Research
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
Samsung Biologics , a leading global CDMO providing end-to-end contract development and manufacturing services, announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier...
Drug Research
Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced that it has entered into a collaboration agreement with Bristol-Myers Squibb Company. This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing...
Drug Research
Agilex Biolabs Toxicology Tapped for SARS-CoV-2 Vaccine Research
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
TetraQ is...
Drug Research
Dr. Reddy’s Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Dr. Reddy's Laboratories Ltd. announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company ("Lilly") for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted emergency...
Drug Research
Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant
The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies. The candidate proved to offer a high level...
Drug Research
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard Pharmaceuticals, a Swedish pharmaceutical company developing and re-positioning drugs in oncology.
Buzzard and 3P began their collaboration at...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.